Status:
TERMINATED
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
Lead Sponsor:
Tufts Medical Center
Conditions:
Central Nervous System Neoplasms
Neoplasm Metastasis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limite...
Detailed Description
High dose chemotherapy and autologous stem cell transplant is an accepted treatment alternative for patients with brain tumors. Temozolomide has been approved for use by the United States Food and Dru...
Eligibility Criteria
Inclusion
- Patients or their health care proxies must be able to provide consent to participate in this trial.
- Patients must have one of the following diagnoses which has not responded or recurred following at least one prior chemotherapy regimen or radiation therapy:
- anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma
- primary CNS lymphoma
- malignant disease metastatic to the CNS
- Patients must be candidates for high dose chemotherapy and autologous stem cell transplant according to the following criteria:
- Patients must be between the ages of 18 and 70 years (inclusive)
- Patients must have a left ventricular ejection fraction greater than or equal to 45% by MUGA or echocardiogram
- Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of predicted
- Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and transaminases less than or equal to 3x institutional upper limit of normal
- Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine clearance greater than or equal to 60 ml/min (either calculated or measured)
- Patients must have an ECOG performance status between 0 and 2
- Patients must be at least 4 weeks from last cytoreductive chemotherapy.
- Expected survival of at least 3 months
Exclusion
- Patients with uncontrolled metastatic disease outside of the CNS which would itself, in the investigator's opinion, limit survival to less than 6 months
- Patients with uncontrolled seizures are ineligible.
- Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or congestive heart failure are ineligible.
- Patients with unstable angina are ineligible.
- Pregnant or lactating women are ineligible.
- Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.
- Patients with uncontrolled, active infection are ineligible.
- Patients infected with HIV are ineligible.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00629187
Start Date
April 1 2004
End Date
April 1 2012
Last Update
April 27 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tufts Medical Center
Boston, Massachusetts, United States, 02111